PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-83.05%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
7.21%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
7.21%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
7.01%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
8.82%
EPS growth above 1.5x CRVO's 2.38%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
8.82%
Diluted EPS growth above 1.5x CRVO's 2.38%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.91%
Share reduction more than 1.5x CRVO's 8.74%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.91%
Diluted share reduction more than 1.5x CRVO's 8.74%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
1.55%
OCF growth under 50% of CRVO's 43.92%. Michael Burry might suspect questionable revenue recognition or rising costs.
1.40%
FCF growth under 50% of CRVO's 43.92%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while CRVO stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.07%
10Y OCF/share CAGR in line with CRVO's 99.96%. Walter Schloss would see both as similarly efficient over the decade.
81.18%
5Y OCF/share CAGR at 75-90% of CRVO's 99.61%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
13.88%
3Y OCF/share CAGR under 50% of CRVO's 95.10%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
98.43%
Similar net income/share CAGR to CRVO's 99.98%. Walter Schloss would see parallel tailwinds or expansions for both firms.
78.58%
5Y net income/share CAGR at 75-90% of CRVO's 99.33%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
-7.39%
Negative 3Y CAGR while CRVO is 90.35%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
109.82%
Positive growth while CRVO is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
14.99%
Positive 5Y equity/share CAGR while CRVO is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-59.15%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.48%
Positive asset growth while CRVO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
19.47%
Positive BV/share change while CRVO is negative. John Neff sees a clear edge over a competitor losing equity.
-6.20%
We’re deleveraging while CRVO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-18.94%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
28.45%
SG&A growth well above CRVO's 0.58%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.